Strong sales of Jardiance helped Boehringer Ingelheim have solid first half

Sales of Diabetes therapy Jardiance has helped Boehringer to a solid first half.
The German company have posted pharmaceutical sales of €6.8bn in the six-month period, a €700m increase year-on-year which has been powered by a 45% increase in Jardiance revenues.
Partner with Eli Lilly, Jardiance has been benefiting from new claims that the drug could cut cardiovascular and kidney failure risk in diabetes patients.
Boehringer is also anticipate an upward moments if it can get approval for the SGLT2, an inhibitor for patients with chronic heart failure with and without type 2 diabetes. This has been given a fast track review by the US FDA, however, results for this will not be generates until 2020.
Also to be read out in 2020, is the EMPA KIDNEY trial. This is testing the impact of empagliflozin on the heart and kidneys won patients with chronic kidney disease (with and without type 2 diabetes).